Back to top

Image: Bigstock

NuVasive, Inc.

Read MoreHide Full Article

NuVasive exited the first quarter of 2017 on a mixed note, with earnings beating the Zacks Consensus Estimate and revenues in line with the mark. Per management, the low-margin Biotronic business impacted the quarter’s performance. However, the year-over-year improvement on the top-line front is on account of strong procedural growth in the U.S. as well as internationally. NuVasive’s strong momentum in the U.S. and international businesses in the first quarter raises optimism. We are also optimistic about the company’s recent progress in development of technologies and services for spine surgery. Meanwhile, the company has been trading below the broader Medical Products industry over the last three months. The stock’s valuation is also quite stretched. Further, currency headwind, pricing and reimbursement issues and competitive landscape are major downsides.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NuVasive, Inc. (NUVA) - free report >>

Published in